Home
Products & Services
Support
About
Contact Us
FinancialContent is the trusted provider of stock market information to the media industry.
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Novavax Inc (NQ: NVAX)
4.720 USD  -0.180 (-3.67%)
Official Closing Price  /  Updated: 7:52 PM EDT, Jul 15, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 831,800
Open 4.900
Bid (Size) 4.100 (1)
Ask (Size) 6.500 (5)
Prev. Close 4.900
Today's Range 4.650 - 4.950
52wk Range 0.3400 - 7.900
Shares Outstanding 381,674,924
Dividend Yield N/A
Performance
YTD
+139.59%
+139.59%
1 Month
-7.45%
-7.45%
3 Month
+761.63%
+761.63%
6 Month
+126.92%
+126.92%
1 Year
+247.06%
+247.06%
Top News
More News
Novavax Confirms Accelerated Approval Pathway Available for Licensure of NanoFlu™
Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will utilize the accelerated approval pathway... Read More
from GlobeNewswire News Releases
Novavax and Catalent Biologics Enter Strategic Partnership: Allowing Catalent Biologics to Expand Gene Therapy Footprint with Acquisition of Novavax’ Manufacturing Assets and Capabilities
Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Catalent Biologics’ Paragon Gene Therapy unit, the leading... Read More
from GlobeNewswire News Releases
More News
Read More
Novavax Provides Updates on the Global Pathways to Licensure for ResVax™
from GlobeNewswire News Releases
Novavax Takes Accelerated Approval Pathway For Flu Vaccine Development
category Trading Ideas , Market News , FDA , and 7 more.
from Benzinga
Novavax Inc Rising Today on Above-Average Volume (NVAX)
from Comtex SmarTrend® News Briefs
UPDATE 1-Enanta's lung infection therapy succeeds in mid-stage trial
category companyNews
from Reuters: Company News
REFILE-Enanta's lung infection therapy succeeds in mid-stage trial
category companyNews
from Reuters: Company News
Enanta's lung infection therapy succeeds in mid-stage trial
category companyNews
from Reuters: Company News
Mid-Day Market Update: NovaBay Pharmaceuticals Surges After Amazon Deal; Insys Therapeutics Shares Drop
category INSY , VUZI , SHLO , and 17 more.
from Benzinga
FDA Recommends Novavax Conduct Added Phase 3 Trial On ResVax
category Benzinga , News , Movers , and 5 more.
from Benzinga
48 Biggest Movers From Wednesday
category News , Top Gainers , Losers , and 60 more.
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
   
© Copyright FinancialContent Services, Inc.